SunTrust Banks, Inc. reiterated their hold rating on shares of Crispr Theraptc (NASDAQ:CRSP) in a research report report published on Friday. The firm currently has a $16.00 price target on the stock. SunTrust Banks also issued estimates for Crispr Theraptc’s Q1 2018 earnings at ($0.67) EPS.
CRSP has been the topic of several other research reports. Chardan Capital restated a buy rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Barclays PLC restated a buy rating and set a $29.00 target price on shares of Crispr Theraptc in a research report on Friday, September 8th. Cann restated a hold rating on shares of Crispr Theraptc in a research report on Thursday, November 9th. Finally, Oppenheimer Holdings, Inc. reiterated a market perform rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $23.08.
Shares of Crispr Theraptc (NASDAQ:CRSP) opened at $17.75 on Friday. Crispr Theraptc has a 52-week low of $11.63 and a 52-week high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). Crispr Theraptc had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same quarter in the previous year, the company earned ($2.77) EPS. The firm’s revenue for the quarter was up 54.2% on a year-over-year basis. equities analysts expect that Crispr Theraptc will post -2.49 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/crispr-theraptc-crsp-receives-hold-rating-from-suntrust-banks-inc/1773517.html.
In related news, CEO Rodger Novak sold 18,470 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total transaction of $383,437.20. Following the transaction, the chief executive officer now directly owns 1,148,007 shares of the company’s stock, valued at approximately $23,832,625.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Samarth Kulkarni sold 27,154 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $20.08, for a total value of $545,252.32. Following the transaction, the insider now directly owns 110,893 shares in the company, valued at $2,226,731.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 287,491 shares of company stock worth $5,690,085. 39.98% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in Crispr Theraptc by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the period. Capital Investment Advisory Services LLC acquired a new position in Crispr Theraptc during the 3rd quarter worth approximately $193,000. Ark Investment Management LLC acquired a new position in Crispr Theraptc during the 2nd quarter worth approximately $206,000. Moloney Securities Asset Management LLC acquired a new position in Crispr Theraptc during the 3rd quarter worth approximately $235,000. Finally, Bank of New York Mellon Corp acquired a new position in Crispr Theraptc during the 3rd quarter worth approximately $288,000. 25.61% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with our FREE daily email newsletter.